Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...
Shares of Entrada Therapeutics rose after regulators removed a clinical hold and said its lead product candidate could be studied as a treatment for Duchenne muscular dystrophy. The stock was up 9.5% ...
Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with ...
Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy - - Follows recently received ...
The Netflix documentary “The Remarkable Life of Ibelin” tells Mats’ story, nearly 10 years after he passed away from a serious muscle condition. He touched countless lives through the online ...
Avidity Biosciences specializes in RNA-based therapies using Antibody-oligonucleotide conjugates to deliver drugs directly to ...
Entrada Therapeutics (TRDA) announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and ...
WHO Wants To Be A Millionaire fans have been left baffled after a famous face used one of their lifelines on an ‘easy ...
Capricor Therapeutics filed a BLA for deramiocel, showing promising results in slowing cardiac dysfunction in DMD ...
Beqvez was Pfizer's first gene therapy, stemming from an alliance with Spark Therapeutics (now part of Roche) more than a ...